Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905252 · ClinicalTrials.gov registry record
Biomarkers for Human Heart Failure
A clinical trial of CHF, sponsored by Mayo Clinic.
- Completed
- Registry status
- 535
- Enrollment target
- 1
- Study location
NCT03905252: Completed study of CHF, sponsored by Mayo Clinic.
NCT03905252 is a study of CHF that has completed, run by Mayo Clinic. The registered enrollment target is 535 participants, above the 92-participant average among 5 other CHF trials with a reported enrollment target (482% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905252, a study of CHF, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 535 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well as history reviews.
Primary Outcome
This study will provide new knowledge of the pathology and outcomes predicted by the use of uAGT in symptomatic chronic HF patients at high risk for future hospitalization and death.
Conditions Studied
Interventions
- OTHER sample analysis
Study Locations (1)
Minnesota
- Mayo Foundation - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2009-08 |
| Est. Completion | 2024-02 |
What the finished NCT03905252 record still lists
NCT03905252 is an observational study that tracks outcomes without assigning an intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, above the 92-participant average among 5 other CHF trials with a reported enrollment target (482% higher).
The record links to 1 condition, with CHF appearing as the primary indexed condition, and to 1 intervention - of which sample analysis is the first listed.
NCT03905252 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03905252 about?
NCT03905252 is a clinical study titled "Biomarkers for Human Heart Failure". The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well...
What is the current status of trial NCT03905252?
This trial is currently completed. The enrollment target is 535 participants. The study started on 2009-08. Estimated completion is 2024-02.
What conditions does trial NCT03905252 study?
This clinical trial studies the following conditions: CHF.
What interventions are being tested in trial NCT03905252?
The interventions under investigation include: sample analysis (OTHER).
Who is sponsoring clinical trial NCT03905252?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905252 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CHF
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)
RECRUITING
-
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
RECRUITING · NA
-
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
COMPLETED · Phase 1
-
A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD
COMPLETED · NA
-
Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia